Nathalie Hafner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nathalie Hafner has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Dirk Weuster-Botz
School of Engineering and Design, Chair of Biochemical Engineering, Technical University of Munich, Garching, Germany
2 shared publications - Maximilian Nicolas Honemann
Department of Physics, Biomolecular Nano‐Technology Technical University of Munich Garching Germany
2 shared publications Hendrik Dietz
Department of Physics, Biomolecular Nano‐Technology Technical University of Munich Garching Germany
1 shared publication- Hendrik Dietz
Department of Biosciences, School of Natural Sciences, Technical University of Munich, Garching, Germany
1 shared publication - Nazanin Nematzadeh Somehsaraei
School of Engineering and Design, Biochemical Engineering, Technical University of Munich, 85748 Garching, Germany
1 shared publication - Wiebke Winkler
School of Engineering and Design, Biochemical Engineering Technical University of Munich Garching Germany
1 shared publication
Latest Publications
- Open Access
- 5 August 2026
- Published by Wiley in Biotechnology and Bioengineering
Scalable Separation and Purification of M13‐Bacteriophage‐Derived Particles Containing Artificial Single‐Stranded DNA Produced by Escherichia coli
Single‐stranded DNA (ssDNA) solutions are promising innovations shaping the future of genetic research and medical therapies. In principle, biotechnological mass production of ssDNA can be achieved using Escherichia coli in a high‐cell density fed‐batch process by secreting phagemid particles derived from the filamentous M13 bacteriophages. However, the production of user‐defined ssDNA enveloped in phagemid particles results in partial lysis of E. coli cells, affecting their sedimentation behavior, thereby complicating cell separation in disc‐stack centrifuge processing. We have demonstrated that complete cell removal can be achieved using tangential flow microfiltration, although the M13 bacteriophage‐derived particles, due to their 900 nm length and 6 nm diameter, pose a challenge for tangential flow filtration. Endonuclease‐mediated nonspecific DNA digestion improved cross‐flow microfiltration, enabling phagemid particle transmission above 90% without degrading the ssDNA product, which remained protected within the phagemid particle's protein shell. In a second cross‐flow ultrafiltration, the M13‐derived particles were concentrated by a factor of 10 and washed by diafiltration. A 750 kDa cut‐off was found to be appropriate for ultrafiltration, quantitatively retaining the phagemid particles during concentration and diafiltration. With this step, the previously used addition of polyethylene glycol 8000 and NaCl for phagemid particle agglomeration and precipitation can be completely replaced, thereby making this new scalable purification process more suitable for pharmaceutical production.
- 5 August 2026
- Published by Wiley in Biotechnology and Bioengineering
Open AccessScalable Separation and Purification of M13‐Bacteriophage‐Derived Particles Containing Artificial Single‐Stranded DNA Produced by Escherichia coli
Single‐stranded DNA (ssDNA) solutions are promising innovations shaping the future of genetic research and medical therapies. In principle, biotechnological mass production of ssDNA can be achieved using Escherichia coli in a high‐cell density fed‐batch process by secreting phagemid particles derived from the filamentous M13 bacteriophages. However, the production of user‐defined ssDNA enveloped in phagemid particles results in partial lysis of E. coli cells, affecting their sedimentation behavior, thereby complicating cell separation in disc‐stack centrifuge processing. We have demonstrated that complete cell removal can be achieved using tangential flow microfiltration, although the M13 bacteriophage‐derived particles, due to their 900 nm length and 6 nm diameter, pose a challenge for tangential flow filtration. Endonuclease‐mediated nonspecific DNA digestion improved cross‐flow microfiltration, enabling phagemid particle transmission above 90% without degrading the ssDNA product, which remained protected within the phagemid particle's protein shell. In a second cross‐flow ultrafiltration, the M13‐derived particles were concentrated by a factor of 10 and washed by diafiltration. A 750 kDa cut‐off was found to be appropriate for ultrafiltration, quantitatively retaining the phagemid particles during concentration and diafiltration. With this step, the previously used addition of polyethylene glycol 8000 and NaCl for phagemid particle agglomeration and precipitation can be completely replaced, thereby making this new scalable purification process more suitable for pharmaceutical production.
- Open Access
- 9 December 2024
- Published by MDPI AG in Applied Sciences
- Vol. 14 (23) , 11459
Early Infection for Mass Production of Artificial Single-Stranded DNA with Escherichia coli
Large quantities of artificial single-stranded DNA (ssDNA) with user-defined sequences are increasingly required to exploit the potential of DNA nanotechnology. Cross-contamination-free ssDNA production can be achieved using Escherichia coli with an optimized helper plasmid in high-cell-density cultivation via the secretion of phagemid particles containing ssDNA with user-defined sequences. In our study, we aimed to reduce the number of phagemid particles for the initiation of ssDNA production. We tested different infection densities, ranging from a multiplicity of infection (MOI) of 10−6–10−2 tfu cfu−1 at the start of the initial batch phase in a 2.5 L stirred tank bioreactor. A MOI of 10−3 tfu cfu−1 was the best compromise between process time and ssDNA concentration. Early initiation of ssDNA production with low MOI reduced the number of phagemid particles by a factor of 250,000. The early infection strategy was successfully scaled up to the 25 L scale, resulting in ssDNA concentrations of >100 mg L−1 within a process time of one day. Transferring the infection strategy to a 1000 L scale gained 65 mg L−1 ssDNA because of incomplete initial infection. The versatility of the early infection strategy was further proven with a second prolonged, user-defined ssDNA sequence.
- 9 December 2024
- Published by MDPI AG in Applied Sciences
- Vol. 14 (23) , 11459
Open AccessEarly Infection for Mass Production of Artificial Single-Stranded DNA with Escherichia coli
Large quantities of artificial single-stranded DNA (ssDNA) with user-defined sequences are increasingly required to exploit the potential of DNA nanotechnology. Cross-contamination-free ssDNA production can be achieved using Escherichia coli with an optimized helper plasmid in high-cell-density cultivation via the secretion of phagemid particles containing ssDNA with user-defined sequences. In our study, we aimed to reduce the number of phagemid particles for the initiation of ssDNA production. We tested different infection densities, ranging from a multiplicity of infection (MOI) of 10−6–10−2 tfu cfu−1 at the start of the initial batch phase in a 2.5 L stirred tank bioreactor. A MOI of 10−3 tfu cfu−1 was the best compromise between process time and ssDNA concentration. Early initiation of ssDNA production with low MOI reduced the number of phagemid particles by a factor of 250,000. The early infection strategy was successfully scaled up to the 25 L scale, resulting in ssDNA concentrations of >100 mg L−1 within a process time of one day. Transferring the infection strategy to a 1000 L scale gained 65 mg L−1 ssDNA because of incomplete initial infection. The versatility of the early infection strategy was further proven with a second prolonged, user-defined ssDNA sequence.